Prototype biomarker could distinguish between healthy and disruptive gut microbiota


The Microbiome Health Index for Post-Antibiotic Dysbiosis was developed to improve understanding and management of risks associated with antibiotic administration.

A first-of-its-kind prototype biomarker from Ferring Pharmaceuticals and Rebiotix could distinguish post-antibiotic disturbances of human gut microbiota, known as dysbiosis, from healthy gut microbiota.

According to a press release, the Microbiome Health Index for Post-Antibiotic Dysbiosis (MHI-A) was developed to improve the understanding and management of risks associated with antibiotic administration. This could help guide the development of live biotherapeutics, which could be a potential new class of drugs, experts say.

The gut microbiome is an incredibly diverse microbial community that is essential to human health, although antibiotics often disrupt microbiome composition and diversity. This disruption is a risk factor for multiple serious diseases, including It’s hard infection and potential recurrences.

Although the impact of antibiotic use on dysbiosis is documented, measuring dysbiosis is complex and approaches often vary from study to study, requiring a simple biomarker to identify the composition of the gut microbiota and help support diagnostic decisions, according to the study.

“This biomarker provides a concise measure to assess complex changes in the microbiome of trial participants before and after treatment, expanding our understanding of microbiome restoration after antibiotic use,” said lead author Ken Blount, PhD, Chief Scientific Officer of Rebiotix and Vice President of Microbiome Research at Ferring Pharmaceuticals, in the press release.

C difference. The infection is a serious and life-threatening illness in which the bacteria cause debilitating symptoms including severe diarrhea, fever, stomach tenderness or pain, loss of appetite, nausea, and colitis. It causes approximately half a million illnesses and tens of thousands of deaths in the United States each year, and has been declared a public health threat by the CDC, requiring urgent and immediate action.

infection by C difference. often causes a cycle of recurrences, with a significant burden on patients and the healthcare system. Up to 35% off C difference. cases recur after initial diagnosis, and people who have had a recurrence are at significantly higher risk of new infections. Restoration of the gut microbiota is increasingly accepted as a promising treatment option for C difference. infection, according to the press release.

The MHI-A algorithm was designed to differentiate post-antibiotic dysbiosis from healthy microbiota. It does this by using the relative abundances of bacteria that are naturally found in the gut microbiome and are associated with health.[DJ1] . According to the press release, the study found that MHI-A has high accuracy in distinguishing post-antibiotic dysbiosis from healthy microbiota.

MHI-A was developed using longitudinal data from over 200 patients treated in 3 controlled clinical trials with leading microbiome-based investigational live biotherapeutics for recurrence reduction C difference. infection. It has been validated using published data describing the microbiome of several healthy and antibiotic-treated populations.

MHI-A values ​​were consistent across multiple healthy populations and were significantly altered by antibiotic treatments known to alter microbiota compositions. In addition, the values ​​are less shifted by microbiota-sparing antibiotics.

According to the press release, the researchers concluded that MHI-A is a promising biomarker for post-antibiotic dysbiosis and subsequent restoration. It may also be useful for classifying the microbiota-disrupting effects of antibiotics and as a pharmacodynamic measure of microbiota restoration.


Frontiers in microbiology publishes a paper detailing a novel microbiome-based biomarker of post-antibiotic gut microbiota disruptions. Press release. Business Wire; January 7, 2022. Accessed January 13, 2022. Microbiota


Comments are closed.